Virpax Pharmaceuticals (NASDAQ:VRPX) Upgraded at Maxim Group

Maxim Group upgraded shares of Virpax Pharmaceuticals (NASDAQ:VRPX) from a hold rating to a buy rating in a research report report published on Friday, Marketbeat Ratings reports. They currently have $3.00 price target on the stock.

Virpax Pharmaceuticals Trading Up 32.8 %

Shares of Virpax Pharmaceuticals stock opened at $1.70 on Friday. Virpax Pharmaceuticals has a one year low of $0.46 and a one year high of $9.77. The company has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $2.53.

Virpax Pharmaceuticals (NASDAQ:VRPX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($2.75) EPS for the quarter.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.